Back in December we reported on the FDA cautioning practioners about the use of gadolinium (an mri contrast agent) in patients with chronic kidney disease. The FDA is now requesting a black box warning stating “that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, …
Clinical Correlations
The NYU Langone Health Online Journal of Medicine
Not So Rosi…
Commentary by Seagram Villagomez MD, Chief Resident
Since its approval in 1999, nearly 1 million Americans have used the thiazolidinedione (TZD) rosiglitazone (Avandia – GlaxoSmithKline) for the treatment of Type 2 Diabetes. However, in a drug class which seems plagued …
ShortCuts-This Week in the Journals
May 21, 2007
This week’s review is a potpourri of interesting if not groundbreaking articles.
The pharmaceutical industry certainly got off easier this week (see last week’s shortcuts) and the New York Times focused instead on the “industrialization” of the art of medicine. A hospital group …
Clinical Pathology Conference 5/11/07-The Answer
May 18, 2007Please review the posting of last week’s CPC Case here.
When you’re ready you can download the CPC Answer here.
Clinical Pharmacy Corner-The Thiazides
May 17, 2007We’d like to introduce you to Clinical Correlations’ newest feature-Clinical Pharmacy Corner. This will be a bimonthly pharmacy themed post which will tackle both basic and complicated pharmacy issues. We will review the mechanisms of actions of various classes of medications, a worthwhile refresher for those of us …
Mystery Quiz #3-The Answer
May 15, 2007Before you read the answer you should read the orginal post form last week
The Final Poll Results (26 votes): metastatic disease (26%) , mycobacterial disease (22%) ,fungal disease (22%), bronchiolitis obliterans with organizing pneumonia (boop) (13%), septic emboli (9%) ,vasculitis, e.g. wegener’s (4%), thromboembolic disease (4%), sarcoid (0%)
ShortCuts-The War on the Pharmaceutical Industry Edition
May 14, 2007
Welcome to our first theme issue of ShortCuts. This week, we decided to focus on the tribulations of the pharmaceutical industry, which recently seems to be plagued by new FDA advisories and NY Times exposés.
The first bad news for pharmaceutical companies occurred …
Meeting Perspectives-Internal Medicine 2007 -The American College of Physicians
May 11, 2007
By: Mitchell Charap, MD Senior Associate Program Director, NYU Internal Medicine Residency Program
The ACP’s annual session is a bit different from other major annual medical meetings. In general it is an excellent review of the prior year’s literature rather than a …